Sanofi to expand its work in China
Date:2008/10/22 Source:
SANOFI-AVENTIS SA, the biggest pharmaceutical company in Europe, announced yesterday it will strengthen e research and development presence in China with a newly signed partnership agreement with the Shanghai Institute for Biological Sciences as well as expanding its current R&D facility in Shanghai.
The partnership program with SIBS will focus on identifying innovative drugs for neurological disease, diabetes and cancer. The French-based drug maker also announced the completion of its new biometrics center in Beijing.
The newly-established biometrics center will support global and local trials in both pharmaceutical and vaccine development and handle the testing, data management and statistical analysis of phase I-IV clinical trials. This new subsidiary is planned to be fully operational by the end of the year.
Marc Cluzel, senior vice president for science and medical affairs, said in Beijing yesterday that "S-A's target in China is to ensure that the latest breakthrough in scientific discoveries can be rapidly converted into applications for treating disease."
Wu Jiarui, vice president of Shanghai Institute for Biological Sciences, noted a committee set up by both parties would carry on talks in the near future to decide on specific research projects.
In addition to the new co-fund research project, S-A would also set up a scholarship program to nurture scientific research talent in China.
Welcome to our website. This service is open to member only.
Contact our customer service team
Tel: 86-10-82600828, 82601561
Email: report@researchinchina.com